Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML
Status:
Recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
MRD driven study. Addition of gemtuzumab to conventional chemotherapy to reduce MRD of
patients with favorable/intermediate-risk AML. Post-consolidation assessment of MRD. Role of
a post-SCT maintenance with glasdegib.